



US009511037B2

(12) **United States Patent**
Desai

(10) **Patent No.:** **US 9,511,037 B2**
(45) **Date of Patent:** **Dec. 6, 2016**

(54) **COMPOSITIONS FOR REDUCTION OF SIDE EFFECTS**

(2013.01); *A61K 31/138* (2013.01); *A61K 31/165* (2013.01); *A61K 31/4168* (2013.01); *A61K 45/06* (2013.01)

(71) Applicant: **Subhash Desai**, Wilmette, IL (US)

(58) **Field of Classification Search**
CPC .. *A61K 2300/00*; *A61K 45/06*; *A61K 31/137*; *A61K 31/55*; *A61K 31/00*; *A61K 31/519*
See application file for complete search history.

(72) Inventor: **Subhash Desai**, Wilmette, IL (US)

(73) Assignee: **GENCO SCIENCES LLC**, Wilmette, IL (US)

(56) **References Cited**

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

U.S. PATENT DOCUMENTS

5,145,648 A 9/1992 Miyahara et al.
5,213,808 A * 5/1993 Bar-Shalom et al. 424/473
(Continued)

(21) Appl. No.: **13/656,415**

FOREIGN PATENT DOCUMENTS

(22) Filed: **Oct. 19, 2012**

WO 2004/071501 8/2004
WO 2011133980 A1 10/2011
WO 2011156710 A2 12/2011

(65) **Prior Publication Data**

US 2013/0039960 A1 Feb. 14, 2013

OTHER PUBLICATIONS

Related U.S. Application Data

Scahill et al ("A Placebo-Controlled Study of Guanfacine in the Treatment of Children With Tic Disorders and Attention Deficit Hyperactivity Disorder." Am J Psychiatry, 2001; 158:1067-1074).*
(Continued)

(63) Continuation-in-part of application No. 13/093,662, filed on Apr. 25, 2011.

(60) Provisional application No. 61/550,119, filed on Oct. 21, 2011, provisional application No. 61/609,590, filed on Mar. 12, 2012, provisional application No. 61/327,486, filed on Apr. 23, 2010, provisional application No. 61/369,338, filed on Jul. 30, 2010.

Primary Examiner — Wu-Cheng Winston Shen
Assistant Examiner — Rayna B Rodriguez
(74) *Attorney, Agent, or Firm* — Casimir Jones, S.C.

(51) **Int. Cl.**

A61K 45/06 (2006.01)
A61K 9/14 (2006.01)
A61K 31/138 (2006.01)
A61K 31/137 (2006.01)
A61K 31/165 (2006.01)
A61K 31/4168 (2006.01)

(57) **ABSTRACT**

The present invention provides drug therapy formulations. In some embodiments, the present invention provides combinations of pharmaceutical agents (e.g., stimulant and non-stimulant), pharmaceutical formulations (e.g., nanoparticulate, non-nanoparticulate, etc.), and release profiles (e.g., immediate release, delayed release, sustained release, etc.) to provide therapeutic benefit with reduced side effects.

(52) **U.S. Cl.**

CPC *A61K 31/137* (2013.01); *A61K 9/14*

21 Claims, 17 Drawing Sheets

